Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease

Future Cardiology

Volumn 6, Issue 3, 2010, Pages 289-299

  Sobieraj Teague, Magdalena ^a   Eikelboom, John W ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antiplatelet agent; Assessment; Platelet function; Point of care

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PLACEBO;

ANALYTICAL EQUIPMENT; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR DISEASE; CLINICAL EVALUATION; DRUG MEGADOSE; HEART DEATH; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; POINT OF CARE TESTING; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; STANDARDIZATION; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION;

ADMINISTRATION, ORAL; ASPIRIN; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; POINT-OF-CARE SYSTEMS; TICLOPIDINE;

EID: 77952524900     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/fca.10.20     Document Type: Review

References (61)

1. Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (7329), 71-86 (2002).
2. Johnson ES, Lanes SF, Wentworth CE 3rd, Satterfield MH, Abebe BL, Dicker LW: A metaregression analysis of the dose-response effect of aspirin on stroke. Arch. Intern. Med. 159 (11), 1248-1253 (1999).
3. Burch J W, Stanford N, Majerus PW: Inhibition of platelet prostaglandin synthetase by oral aspirin. J. Clin. Invest. 61 (2), 314-319 (1978).
4. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69 (6), 1366-1372 (1982).
5. Smith SC Jr, Allen J, Blair SN et al.: AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute. J. Am. Coll. Cardiol. 47 (10), 2130-2139 (2006). (Pubitemid 44275145)
6. Becker RC, Meade TW, Berger PB et al.: The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 Suppl.), 776S-814S (2008).
7. Mofflat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP: Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb. Haemost. 93 (3), 549-553 (2005).
8. Steinhubl SR, Talley JD, Braden GA et al.: Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 103 (21), 2572-2578 (2001).
9. Angiolillo DJ: Variability in responsiveness to oral antiplatelet therapy. Am. J. Cardiol. 103 (3 Suppl.), 27A-34A (2009).
10. Wang TH, Bhatt DL, Topol EJ: Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J. 27 (6), 647-654 (2006).
11. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR: Aspirin 'resistance' and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336 (7637), 195-198 (2008). Reference meta-analysis assessing the relationship of aspirin resistance and adverse clinical outcomes.
12. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV: Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch. Intern. Med. 167 (15), 1593-1599 (2007).
13. Sof F, Marcucci R, Gori AM, Abbate R, Gensini GF: Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events - a meta-analysis. Int. J. Cardiol. 128 (2), 166-171 (2008).
14. Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G: Response variability to aspirin as assessed by the platelet function analyzer (PFA) -100. A systematic review. Thromb. Haemost. 99 (1), 14-26 (2008).
15. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV: Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154 (2), 221-231 (2007). Reference meta-analysis reviewing evidence on the prevalence and clinical consequences of laboratory clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention.
16. Jakubowski JA, Payne CD, Li YG et al.: The use of the VerifyNow P2Y12 point-ofcare device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb. Haemost. 99 (2), 409-415 (2008).
17. Malinin A, Pokov A, Swaim L, Kotob M, Serebruany V: Validation of a VerifyNow-P2Y12 cartridge for monitoring platelet inhibition with clopidogrel. Methods Find. Exp. Clin. Pharmacol. 28 (5), 315-322 (2006).
18. van Werkum JW, van der Stelt CA, Seesing TH, Hackeng CM, ten Berg JM: A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention. J. Thromb. Haemost. 4 (11), 2516-2518 (2006).
19. Smith JW, Steinhubl SR, Lincoff AM et al.: Rapid platelet-function assay: an automated and quantitative cartridgebased method. Circulation 99 (5), 620-625 (1999).
20. Wheeler GL, Braden GA, Steinhubl SR et al.: The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. Am. Heart J. 143 (4), 602-611 (2002).
21. von Beckerath N, Pogatsa-Murray G, Wieczorek A, Sibbing D, Schomig A, Kastrati A: Correlation of a new point-of-care test with conventional optical aggregometry for the assessment of clopidogrel responsiveness. Thromb. Haemost. 95 (5), 910-911 (2006).
22. Chen WH, Lee PY, Ng W et al.: Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am. J. Cardiol. 96 (6), 760-763 (2005).
23. Chen WH, Lee PY, Ng W, Tse HF, Lau CP: Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. J. Am. Coll. Cardiol. 43 (6), 1122-1126 (2004).
24. Marcucci R, Gori AM, Paniccia R et al.: Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119 (2), 237-242 (2009). Demonstrates that hypo responsiveness to clopidogrel as determined by the VerifyNow P2Y12 assay predicts cardiovascular death and nonfatal myocardial infarction at 12 months.
25. Patti G, Nusca A, Mangiacapra F, Gatto L, Dambrosio A, Di Sciascio G: Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty - Platelet Reactivity Predicts Outcome) study. J. Am. Coll. Cardiol. 52 (14), 1128-1133 (2008).
26. Price MJ, Endemann S, Gollapudi RR et al.: Prognostic significance of postclopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29 (8), 992-1000 (2008).
27. Favaloro EJ: Clinical utility of the PFA-100. Semin. Thromb. Hemost. 34 (8), 709-733 (2008).
28. Paniccia R, Antonucci E, Gori AM et al.: Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients. J. Thromb. Haemost. 5 (9), 1839-1847 (2007).
29. Geiger J, Teichmann L, Grossmann R et al.: Monitoring of clopidogrel action: comparison of methods. Clin. Chem. 51 (6), 957-965 (2005).
30. Kotzailias N, Elwischger K, Sycha T et al.: Clopidogrel-induced platelet inhibition cannot be detected by the platelet function analyzer-100 system in stroke patients. J. Stroke Cerebrovasc. Dis. 16 (5), 199-202 (2007).
31. Reny JL, De Moerloose P, Dauzat M, Fontana P: Use of the PFA-100 closure time to predict cardiovascular events in aspirintreated cardiovascular patients: a systematic review and meta-analysis. J. Thromb. Haemost. 6 (3), 444-450 (2008). Meta-analysis of clinical predictive value of Platelet Function Assay-100 system in aspirin-treated cardiovascular patients.
32. Crescente M, Di Castelnuovo A, Iacoviello L, de Gaetano G, Cerletti C: PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a meta-ana lysis of 19 studies comprising 3, 003 patients. Thromb. Haemost. 99 (6), 1129-1131 (2008).
33. van Werkum JW, Kleibeuker M, Postma S et al.: A comparison between the Plateletworks ®-assay and light transmittance aggregometry for monitoring the inhibitory effects of clopidogrel. Int. J. Cardiol. DOI:10.1016/j.ijcard. 2008.10.046 (2008) (Epub ahead of print).
34. Craft RM, Chavez JJ, Snider CC, Muenchen RA, Carroll RC: Comparison of modified Thrombelastograph and Plateletworks whole blood assays to optical platelet aggregation for monitoring reversal of clopidogrel inhibition in elective surgery patients. J. Lab. Clin. Med. 145 (6), 309-315 (2005).
35. White MM, Krishnan R, Kueter TJ, Jacoski MV, Jennings LK: The use of the point of care Helena ICHOR/Plateletworks and the Accumetrics Ultegra RPFA for assessment of platelet function with GPIIB-IIIa antagonists. J. Thromb. Thrombolysis 18 (3), 163-169 (2004).
36. Ray MJ, Walters DL, Bett N, Cameron J, Wood P, Aroney C: Point-of-care testing shows clinically relevant variation in the degree of inhibition of platelets by standarddose abciximab therapy during percutaneous coronary intervention. Catheter. Cardiovasc. Interv. 62 (2), 150-154 (2004).
37. Craft RM, Chavez JJ, Bresee SJ, Wortham DC, Cohen E, Carroll RC: A novel modification of the thrombelastograph assay, isolating platelet function, correlates with optical platelet aggregation. J. Lab. Clin. Med. 143 (5), 301-309 (2004).
38. Swallow RA, Agarwala RA, Dawkins KD, Curzen NP: Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy? Platelets 17 (6), 385-392 (2006).
39. Tantry US, Bliden KP, Gurbel PA: Overestimation of platelet aspirin resistance detection by thrombelastograph platelet mapping and validation by conventional aggregometry using arachidonic acid stimulation. J. Am. Coll. Cardiol. 46 (9), 1705-1709 (2005).
40. Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA: Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate? J. Am. Coll. Cardiol. 49 (6), 657-666 (2007).
41. Osende JI, Fuster V, Lev EI et al.: Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: relevance for monitoring long-term glycoprotein IIb/IIIa inhibition. Circulation 103 (11), 1488-1491 (2001).
42. Shenkman B, Schneiderman J, Tamarin I, Kotev-Emeth S, Savion N, Varon D: Testing the effect of GPIIb-IIIa antagonist in patients undergoing carotid stenting: correlation between standard aggregometry, flow cytometry and the cone and plate (let) analyzer (CPA) methods. Thromb. Res. 102 (4), 311-317 (2001).
43. Hankey GJ, Eikelboom JW: Aspirin resistance. BMJ 328 (7438), 477-479 (2004). Comprehensive critical review of aspirin resistance.
44. Maree AO, Fitzgerald DJ: Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation 115 (16), 2196-2207 (2007).
45. Nguyen TA, Diodati JG, Pharand C: Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol. 45 (8), 1157-1164 (2005).
46. Lev EI, Patel RT, Maresh KJ et al.: Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J. Am. Coll. Cardiol. 47 (1), 27-33 (2006).
47. Bonello L, Camoin-Jau L, Armero S et al.: Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am. J. Cardiol. 103 (1), 5-10 (2009). Randomized controlled trial demonstrating that tailored clopidogrel therapy according to platelet reactivity in patients undergoing percutaneous coronary intervention decreases adverse events.
48. Angiolillo DJ, Shoemaker SB, Desai B et al.: Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 115 (6), 708-716 (2007).
49. Angiolillo DJ, Costa MA, Shoemaker SB et al.: Functional effects of high clopidogrel maintenance dosing in patients with inadequate platelet inhibition on standard dose treatment. Am. J. Cardiol. 101 (4), 440-445 (2008).
50. Cuisset T, Frere C, Quilici J et al.: Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48 (7), 1339-1345 (2006).
51. Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US: The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45 (9), 1392-1396 (2005).
52. Bonello L, Camoin-Jau L, Arques S et al.: Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J. Am. Coll. Cardiol. 51 (14), 1404-1411 (2008). First study to suggest that adjusted clopidogrel loading dose according to platelet monitoring may improve clinical outcomes after percutaneous coronary intervention in patients with clopidogrel hyporesponsiveness.
53. Angiolillo DJ, Capranzano P, Goto S et al.: A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Eur. Heart J. 29 (18), 2202-2211 (2008).
54. Jeong YH, Lee SW, Choi BR et al.: Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high posttreatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J. Am. Coll. Cardiol. 53 (13), 1101-1109 (2009).
55. Storey RF, Husted S, Harrington RA et al.: Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J. Am. Coll. Cardiol. 50 (19), 1852-1856 (2007).
56. Brandt JT, Payne CD, Wiviott SD et al.: A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am. Heart J. 153 (1), 66E69-E16 (2007).
57. Jakubowski JA, Payne CD, Li YG et al.: A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb. Haemost. 99 (1), 215-222 (2008).
58. Wallentin L, Varenhorst C, James S et al.: Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29 (1), 21-30 (2008).
59. Cuisset T, Frere C, Quilici J et al.: Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc. Interv. 1 (6), 649-653 (2008).
60. Michelson AD, Cattaneo M, Eikelboom JW et al.: Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost. 3 (6), 1309-1311 (2005).
61. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al.: ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113 (1), 156-175 (2006).